A feasibility study of chemotherapy with vinorelbine plus bevacizumab in elderly patients with non-small lung cancer
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000005800
- Lead Sponsor
- Toho University Omori Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Not provided
1) Receiving a blood transfusion, hematopoietic factor, anticoagulant drug 2 weeks prior to enrollment. 2) Severe renal function disorder 2+ or higher proteinuria within 2 weeks prior to enrollment. 3) Serious drug allergy. 4) Active synchronous malignancies. 5) Uncontrolled Active infection. 6) Uncontrollable hypertension, uncontrollable diabetes. 7) Clinically significant heart disease. 8)Thromboembolism, interstitial pneumonia, pulmonary fibrosis and severe emphysema within the past one year. 9)Traumatic fracture of unrecovery 10) Mental disorder, central nervous system disorders, cerebrovascular disorders. 11) Permeation of the neoplastic cell in large vessels. 12) Hollowing out of the tumor. 13) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completion
- Secondary Outcome Measures
Name Time Method Safety Efficacy QOL OS PFS